Feb 11, 2015 8:00 am EST Heat Biologics Presents Positive Preclinical Data on a Novel Approach to Combination Immunotherapy at the Keystone Symposia on Tumor Immunology
Jan 26, 2015 8:00 am EST Heat Biologics, Inc. Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015
Jan 23, 2015 8:00 am EST Heat Biologics, Inc. to Present at the 7th Annual Phacilitate Immunotherapy Forum 2015
Jan 15, 2015 8:00 am EST Heat Biologics, Inc. to Present at the Noble Financial Capital Markets Equity Conference
Dec 02, 2014 8:00 am EST Heat Biologics, Inc. Expands Product Development Team to Support Development of Lead Product Candidates in Oncology
Dec 01, 2014 8:00 am EST Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
Oct 27, 2014 8:05 am EDT Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer